<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03592862</url>
  </required_header>
  <id_info>
    <org_study_id>HTL0018318-203</org_study_id>
    <nct_id>NCT03592862</nct_id>
  </id_info>
  <brief_title>A Study to Assess Safety, Tolerability, and Efficacy of HTL0018318 in Patients With Dementia With Lewy Bodies</brief_title>
  <acronym>DLB</acronym>
  <official_title>A Randomized, Double-blind, Placebo Controlled, Dose Ranging Study to Assess the Safety, Tolerability, and Efficacy of HTL0018318 in Patients With Dementia With Lewy Bodies</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Heptares Therapeutics Limited</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Sosei</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Heptares Therapeutics Limited</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      To establish the safety and efficacy of HTL0018318 compared with placebo when administered
      once daily for 12 weeks to patients with dementia with Lewy bodies.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      To assess the safety, tolerability and efficacy of HTL0018318 at 3 dose levels (once daily)
      compared with placebo over a 12-week treatment period in patients with dementia with Lewy
      bodies (DLB). Approximately 140 DLB patients who have not received donepezil (AriceptÂ®)
      and/or other acetyl cholinesterase inhibitors (AchEi) and approximately 32 DLB patients who
      have had prior treatment experience with donepezil but have stopped usage will be enrolled.
    </textblock>
  </detailed_description>
  <overall_status>Withdrawn</overall_status>
  <why_stopped>
    Pending investigation of an unexpected animal toxicology finding.
  </why_stopped>
  <start_date type="Anticipated">July 2019</start_date>
  <completion_date type="Anticipated">January 2021</completion_date>
  <primary_completion_date type="Anticipated">July 2020</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Placebo controlled</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
    <masking_description>Double blind</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Incidence and severity of treatment related adverse events</measure>
    <time_frame>Baseline to 12 weeks</time_frame>
    <description>Comparison of HTL0018318 treatment with placebo</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in systolic, diastolic blood pressure and heart rate</measure>
    <time_frame>Baseline to 12 weeks</time_frame>
    <description>Comparison of HTL0018318 treatment with placebo</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in measures of cognitive impairment</measure>
    <time_frame>Baseline to 12 weeks</time_frame>
    <description>Comparison of HTL0018318 treatment with placebo</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in measures of psychosis (i.e. hallucinations and delusions)</measure>
    <time_frame>Baseline to 12 weeks</time_frame>
    <description>Comparison of HTL0018318 treatment with placebo</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">0</enrollment>
  <condition>Dementia With Lewy Bodies</condition>
  <arm_group>
    <arm_group_label>HTL0018318 high dose</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>oral capsule, once daily</description>
  </arm_group>
  <arm_group>
    <arm_group_label>HTL0018318 mid dose</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>oral capsule, once daily</description>
  </arm_group>
  <arm_group>
    <arm_group_label>HTL0018318 low dose</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>oral capsule, once daily</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>oral capsule, once daily</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>HTL0018318</intervention_name>
    <description>Oral capsule</description>
    <arm_group_label>HTL0018318 high dose</arm_group_label>
    <arm_group_label>HTL0018318 low dose</arm_group_label>
    <arm_group_label>HTL0018318 mid dose</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Oral capsule</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Diagnosed with probable DLB according to the fourth revision of consensus diagnostic
             criteria for DLB.

          -  Clinical imaging evidence from either SPECT or MIBG cardiac scintigraphy that is
             consistent with a clinical diagnosis of DLB.

          -  Partner or caregiver able to support the patient for the duration of the clinical
             trial.

        Exclusion Criteria:

          -  Patients with a diagnosis of Parkinson disease at least 1 year prior to onset of
             dementia.

          -  Patients with the presence of severe extrapyramidal symptoms

          -  Patients with the presence of an illness/condition apart from DLB that could
             contribute to cognitive dysfunction

          -  Patients with poorly controlled hypertension despite lifestyle modifications and/or
             pharmacotherapy, who are currently on more than 2 different antihypertensive
             treatments

          -  Patients with prominent, recurrent episodes of syncope are related to orthostatic
             hypotension

          -  Patients with pulmonary disease or evidence of clinically significant moderate or
             severe pulmonary symptoms

          -  Patients who are taking a range of prohibited and restricted medication

          -  Patients who have been prescribed individualised cognitive rehabilitation, stimulation
             or training that was performed under medical supervision in the 6 months prior to the
             screening visit

          -  Patients who have any known condition(s) that may be contraindicated or interfere with
             the completion of the nuclear imaging scans.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>50 Years</minimum_age>
    <maximum_age>85 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Tim Tasker, MBBS</last_name>
    <role>Study Chair</role>
    <affiliation>Heptares Therapeutics Ltd.</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Nishitaga Hospital</name>
      <address>
        <city>Sendai</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kagawa Prefectural Central Hospital</name>
      <address>
        <city>Takamatsu</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kurumi Clinic</name>
      <address>
        <city>Tokyo</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Japan</country>
  </location_countries>
  <verification_date>September 2019</verification_date>
  <study_first_submitted>June 25, 2018</study_first_submitted>
  <study_first_submitted_qc>July 18, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">July 19, 2018</study_first_posted>
  <last_update_submitted>September 30, 2019</last_update_submitted>
  <last_update_submitted_qc>September 30, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">October 1, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dementia</mesh_term>
    <mesh_term>Lewy Body Disease</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

